BN29553

A Phase III,Multicenter, Randomized,Double-Blind,Placebo-Controlled,Parallel-Group,Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223539

Enrollment

750

Registered

2017-05-24

Start date

2017-12-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease(AD)

Interventions

investigational material(s) Generic name etc : Crenezumab INN of investigational material : Crenezumab Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Meet NIA-AA core clinical criteria for probable AD dementia or prodromal AD -Having mild symptomatology, as defined by a screening MMSE score of 22 points and higher, and CDR-GS of 0.5 or 1.0 etc.

Exclusion criteria

Exclusion criteria: -Any evidence of a condition other than AD that may affect cognition -Meet the exclusion criteria of MRI at screening etc.

Design outcomes

Primary

Measure	Time frame
safety efficacy Observation/Examination	—

Secondary

Measure	Time frame
pharmacokinetics pharmacodynamics Examination	—

Countries

Africa, Asia except Japan, Europe, Japan, North America, Oceania, South America

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026